Did you know?

As of December 31, 2022, INOVIO had 253.1 million common shares outstanding and 271.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.Inovio Pharmaceuticals (INO) Q2 2023 Earnings Call Transcript finance.yahoo.com - August 9 at 9:04 PM: Inovio Pharmaceuticals cuts 30% of staff in third round of layoffs in 13 months bizjournals.com - August 1 at 7:38 PM: Inovio Pharmaceuticals (INO) Stock Up, Begins Recruitment for MERS Vaccine Trial thestreet.com - July 28 at 8:03 AM plymouth meeting, pa., june 23, 2023 (globe newswire) - inovio (nasdaq:ino) has released the following pursuant to an order of the united states district court eastern district of pennsylvania: united states district court eastern district of pennsylvania in re inovio pharmaceuticals, inc. derivative litigation lead case no. 2:20-cv-01962-gjp notice of …

Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Nasdaq 14,295.90 +0.39% +54.88 Russell 1,801.91 +0.042% +0.76 VIX 12.68 -0.079% -0.0100 Home INO • NASDAQ Inovio Pharmaceuticals Inc Follow Share $0.40 Nov 28, 11:47:07 AM GMT-5 · USD ·...Investors, Inovio Get Final OK For $44M Deal In Stock Suit. A Pennsylvania federal judge on Wednesday approved a $44 million deal between biotechnology firm Inovio Pharmaceuticals Inc. and its ...Find the latest analyst research for Inovio Pharmaceuticals, Inc. Common Stock (INO) at Nasdaq.com.

Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial INOVIO also continues to partner with QIAGEN to develop a pre-treatment predictive …WebIn addition, Inovio Pharmaceuticals, Inc. has a VGM Score of D ... Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why 10/19/23-8:53AM EST Zacks Inovio Pharmaceuticals ... ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Inovio pharmaceuticals stock. Possible cause: Not clear inovio pharmaceuticals stock.

Jun 27, 2022 · Inovio Pharmaceuticals (INO-5.75%) stock rose slightly on an otherwise gloomy day for the wider market. Investors were cheered by the appointment of a new chief medical officer at their company. Inovio Pharmaceuticals ( INO) reported Q3 2023 earnings per share (EPS) of -$0.13, meeting estimates of -$0.13 by 0.29%. In the same quarter last year, Inovio Pharmaceuticals 's earnings per share (EPS) was -$0.15. Inovio Pharmaceuticals is expected to release next earnings on 02/28/2024, with an earnings per share (EPS) …Web

INO stock trades near $10 currently and it is, in fact, down 27% from its pre-Covid high of around $14 in early March 2020 – before the coronavirus pandemic hit the world. INO stock has had a ...WebInovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher again on Wednesday after surging more than 40% on Tuesday after the FDA said it can use data from the completed Phase 1 ...

pr stock forecast The year-over-year increase in G&A expenses was primarily due to a $14.0 million non-cash expense related to the settlement of INOVIO's securities class action litigation, including the issuance of INOVIO common stock as part of the settlement, $14.3 million in higher legal expenses, primarily related to litigation matters, $6.9 million in one ... best stock siteshow to trade on forex Inovio Pharmaceuticals: Implied upside of 434%. But the crème de la crème of upside opportunity, at least on this list, is clinical-stage biotech stock Inovio Pharmaceuticals (INO 0.96%).WebOct 27, 2022 · Inovio Pharmaceuticals is a small-ish biotech company with a market cap of around $519 million. The company ended 2022's second quarter with $348 million in cash and short-term investments, which ... fidelity growth mutual funds Inovio Pharmaceuticals, Inc. Common Stock (INO) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an... Nov 9, 2023 · INVESTORS. & MEDIA. Loading... INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. automated trading software freeqbts stocktwitsgantri lamps 52-week High/Low: $2.07 / $0.32. 50/200 Day Moving Average: $0.407 / $0.664. This figure corresponds to the Average Price over the previous 50/200 days. For Inovio Pharmaceuticals stocks, the 50-day moving average is the support level today. For Inovio Pharmaceuticals stocks, the 200-day moving average is the resistance level today.WebInovio Pharmaceuticals (INO) stock price prediction is 2.5270197612807 USD. The Inovio Pharmaceuticals stock forecast is 2.5270197612807 USD for 2024 ... options analytics software Get Inovio Pharmaceuticals Inc (INO.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsMar 1, 2023 · Inovio Pharmaceuticals, Inc. stockholders' equity: Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021 can i buy oil futuresreliance steel and aluminum co.boram postnatal Inovio Pharmaceuticals Stock Performance (As of Friday Closing) Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS; $0.40: $0.39: $0.34 - $2.61: $100M: 268M: 3.45M-$0.65: Inovio Pharmaceuticals Financials Summary. In Thousands, USD TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec …Web